Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
posted on
Jun 22, 2020 09:50AM
Positive news but can I play devils advocate for a moment. There were a number of positive and very robust results that came out of the phase 2 trials that did not play out in BoM. Is there not a similar risk of some of these big HR numbers from BOM meeting a similar fate in BoM2 or should those statistical CI percentages hold up?